Pharmafile Logo

Gilead Sciences Inc

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Gilead Sciences Inc in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Gilead Sciences Inc.

Recent articles on PMLiVE featuring Gilead Sciences Inc

- PMLiVE
Gilead and PAHO announce milestone partnership to accelerate access to HIV pre-exposure treatment

The agreement will improve access to twice-yearly Lenacapavir across Latin America and the Caribbean

- PMLiVE
Gilead opens new research centre bringing together oncology, inflammation and research data science teams

The centre in California supports the company’s $32bn US investment

- PMLiVE
Gilead’s New Drug Application for Yeztugo accepted by US FDA

The investigational once-weekly oral treatment could be the first long-acting pill for HIV prevention

- PMLiVE
Gilead Foundation announces $12m investment through HIV Prevention Initiative

The US state investment will go to 33 community-based organisations

- PMLiVE
Gilead to acquire Arcellx in deal worth $7.8bn

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

- PMLiVE
Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE
Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE
Gilead Sciences and Kymera enter oncology partnership worth up to $750m

The companies will focus on advancing Kymera’s oral molecular glue degrader programme

- PMLiVE
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

More than 100 people in the US were diagnosed with HIV every day in 2023

- PMLiVE
Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

- PMLiVE
LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE
Rare Disease Day 2025 – highlighting recent approvals in the rare disease space

There are more than 7,000 known rare diseases that impact 300 million people globally

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links